Data of patients treated with sintilimab at the Union Hospital Affiliated to Fujian Medical University from January 2015 to May 2022 were retrospectively collected, including patient characteristics (such as age, sex, and alcohol and smoking history), disease characteristics (tumor type, tumor surgical history, pulmonary metastasis, brain metastasis, and number of metastatic sites), characteristics of comorbidities (such as hypertension, diabetes, coronary heart disease, stroke, chronic obstructive pulmonary disease, hepatitis, and syphilis), previous medication history (e.g., chemotherapeutics, targeted drugs, and other PD‐1s), combination therapy (e.g., chemotherapy, targeted drugs, antimicrobials, sputum agents, anti‐asthmatics, glucocorticoids, proton pump inhibitors [PPIs], or pirfenidone), treatment regimen of sintilimab (cycle and single dose), and hematological examination results (routine blood testing, electrolytes, lactate dehydrogenase, liver function, kidney function, and thyroid function indicators). Laboratory index ratios were calculated using the following methods: platelet‐lymphocyte ratio (PLR) = platelet count (×109 cells/L)/lymphocyte count (×109 cells/L) and neutrophil‐to‐lymphocyte ratio (NLR) = absolute neutrophil count (×109 cells/L)/lymphocyte count (×109 cells/L). Clinical data on IRP were collected retrospectively and classified according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.
15
The inclusion criterion for this study was having tumors and receiving sintilimab. The exclusion criteria were as follows: (a) age <18 years, (b) treatment with a combination of sintilimab and other ICIs, (c) dropping out during follow‐up, and (d) missing data. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Fujian Union Medical College Hospital. Due to the retrospective nature of this study, the requirement for written informed consent was waived.
Free full text: Click here